Capricor Therapeutics (NASDAQ:CAPR) Given “Buy” Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of Capricor Therapeutics (NASDAQ:CAPR) in a report released on Tuesday,Benzinga reports. The firm currently has a $77.00 price objective on the biotechnology company’s stock.

Separately, Cantor Fitzgerald upped their price objective on Capricor Therapeutics from $25.00 to $30.00 and gave the company an “overweight” rating in a research note on Thursday, November 14th. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $34.50.

Capricor Therapeutics Trading Up 0.2 %

Capricor Therapeutics stock opened at $13.70 on Tuesday. Capricor Therapeutics has a 12 month low of $3.52 and a 12 month high of $23.40. The business’s 50 day simple moving average is $14.41 and its 200 day simple moving average is $13.87. The company has a market cap of $622.94 million, a price-to-earnings ratio of -12.92 and a beta of 4.08.

Institutional Investors Weigh In On Capricor Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Summit Investment Advisors Inc. raised its holdings in Capricor Therapeutics by 54.1% during the 4th quarter. Summit Investment Advisors Inc. now owns 3,832 shares of the biotechnology company’s stock valued at $53,000 after acquiring an additional 1,345 shares during the period. Russell Investments Group Ltd. increased its holdings in shares of Capricor Therapeutics by 172.8% in the fourth quarter. Russell Investments Group Ltd. now owns 4,652 shares of the biotechnology company’s stock worth $64,000 after purchasing an additional 2,947 shares during the period. Virtus ETF Advisers LLC bought a new position in shares of Capricor Therapeutics in the fourth quarter worth $68,000. AlphaQuest LLC bought a new position in shares of Capricor Therapeutics in the fourth quarter worth $78,000. Finally, New York State Common Retirement Fund increased its holdings in shares of Capricor Therapeutics by 625.0% in the fourth quarter. New York State Common Retirement Fund now owns 5,800 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 5,000 shares during the period. Institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.